<DOC>
	<DOCNO>NCT02497404</DOCNO>
	<brief_summary>The purpose study determine whether 5-Azacytidine prim condition regimen subject receive hematopoietic stem cell transplant effective treatment high risk myeloid malignancy complete remission ( CR ) .</brief_summary>
	<brief_title>Azacytidine Prior Vivo T-cell Depleted Allo Stem Cell Transplant Patients With Myeloid Malignancies CR</brief_title>
	<detailed_description>This open label two-step phase II study design determine safety efficacy epigenetic prim 5-Azacytidine immediately prior reduce intensity condition vivo T-cell deplete hematopoietic stem cell transplantation high risk myeloid malignancy complete remission ( CR ) . Subjects give five day course subcutaneous 5-azacytidine , follow reduce intensity condition regimen fludarabine melphalan prior allogeneic hematopoietic stem cell transplantation relate unrelated HLA match donor . The effect 5-azacytidine global gene methylation assess . Evaluations safety , particular graft failure , transplant relate mortality acute graft versus host disease make weekly basis . Efficacy , define disease free survival , evaluate bone marrow biopsy standard time point , one- , three- , six- , twelve-months transplant upon clinical suspicion within regular follow-up visit - weekly first 3 month , biweekly 3 month , monthly one-year post-SCT . Thereafter , unless otherwise dictate clinical scenario , follow visit every 3 month .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Patients must histologically cytologically confirm AML MDS specify : 1 . Acute myeloid leukemia poor risk cytogenetics ( 1 ) complete hematologic remission . These include : del ( 5q ) /5 , del ( 7q ) /7 , abn 3q , 9q , 11q , 20q , 21q , 17p , ( 6 ; 9 ) , ( 9 ; 22 ) complex karyotype ( â‰¥ 3 unrelated abnormality ) ; 2 . Acute myeloid leukemia Flt3 mutation complete hematologic remission ; 3 . Acute myeloid leukemia , type , exclude M3 ( Promyelocytic leukemia ) second high hematologic remission ; 4 . Myelodysplastic syndrome ( intermediate2 , high risk CMML bone marrow blast &lt; 5 % ) ; Secondary acute myeloid leukemia basis prior MDS hematologic remission Life expectancy severely limited concomitant disease ECOG performance status less equal 2 Adequate organ function define : Serum Bilirubin : &lt; 2.0 mg/dL ALT ( SGPT ) : &lt; 3X upper limit normal Creatinine Clearance : &gt; 50 mL/min ( eGFR estimate modified MDRD equation ) Ability understand willingness sign write informed consent document . Evidence chronic active hepatitis cirrhosis HIV infection Uncontrolled illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant lactate woman exclude study risk unborn fetus potential risk nurse infant unknown . There prior therapy concomitant medication would render patient ineligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>